We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients (MR WITNESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01282242
Recruitment Status : Completed
First Posted : January 24, 2011
Results First Posted : April 11, 2017
Last Update Posted : June 15, 2017
National Institute of Neurological Disorders and Stroke (NINDS)
Genentech, Inc.
Information provided by (Responsible Party):
Lee Schwamm, Massachusetts General Hospital

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Acute Stroke
Intervention: Drug: IV rt-PA

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited between January 2011 and February 2016 from 14 sites across the continental United States, and enrolled in 10 of those sites.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects diagnosed with acute ischemic stroke, last known well within 24 hours of triage and able to receive IV rt-PA within 4.5 hours from symptom discovery based on MRI findings consistent with early stroke onset, were eligible. MRI Signal Intensity Ration values were defined as <1.15 for the primary and <1.25 for the secondary arm of the trial.

Reporting Groups
Primary SIR <1.15 MRI confirmed early stroke onset, determined by Signal intensity ratio (SIR) <1.15 (SIR = Contralateral Region Of Interest (ROI)/Ipsilateral ROI)
Secondary SIR <1.25 MRI confirmed early stroke onset, determined by Signal intensity ratio (SIR) <1.25 (SIR = Contralateral Region Of Interest (ROI)/Ipsilateral ROI)

Participant Flow:   Overall Study
    Primary SIR <1.15   Secondary SIR <1.25
STARTED   80   8 
COMPLETED   80   8 

  Baseline Characteristics

  Outcome Measures

1.  Primary:   Number of Subjects With Symptomatic Intracerebral Hemorrhage   [ Time Frame: Within 7 days from tPA administration. ]

2.  Secondary:   Number of Subjects With Symptomatic Cerebral Edema   [ Time Frame: Within 96 hours of tPA administration ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This was a single arm open label trial. Genetech provided alteplase free of charge for this NINDS sponsored study.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Lee H. Schwamm, MD
Organization: Massachusetts General Hospital
phone: 617-724-1597
e-mail: lschwamm@mgh.harvard.edu

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Lee Schwamm, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01282242     History of Changes
Other Study ID Numbers: 2010P001880
First Submitted: January 19, 2011
First Posted: January 24, 2011
Results First Submitted: February 27, 2017
Results First Posted: April 11, 2017
Last Update Posted: June 15, 2017